Transpek Industry Ltd Q1 FY2023 Concall Summary

Key Takeaways

• Revenue inflated by pass-through, margins compressed: A sharp rise in raw material costs passed to customers (45-50% of business) mechanically depressed EBITDA margin percentage despite healthy absolute EBITDA, while logistics costs and insurance premiums added pressure.
• Volumes restored to pre-COVID levels: Capacity utilization hit 90-92%, comparable to FY2018-2019, with demand for acid and alkyl chlorides remaining strong across pharmaceuticals and polymers.
• Expansion permission secured after years of deadlock: Primary approval obtained for up to 450 MT/month of additional capacity, though pollution control board conditions may restrict the actual increase to 200-250 MT.
• Full-year sales guided at ₹750-800 Crores: Management expects moderate, steady growth from current utilization levels, with some contribution from volume and some from cost pass-through into price.
• What to watch next quarter: Whether the Europe energy crisis begins to disrupt raw material supply or customer demand, the pace of logistics cost reduction, and progress toward final approval on the capacity expansion.

Revenue & Margin Mechanics

• Pass-through distorts the P&L: When raw material costs rise and are passed through to customers, absolute EBITDA may remain healthy but the margin percentage falls mechanically. Management illustrated: 20% EBITDA on ₹100 sales becomes 16.67% on ₹120 sales when ₹20 of cost is added and passed through.
• Logistics costs spiked significantly: Some of this is passed through to customers, but many products quoted on a competitive basis may not sustain earlier margin levels. Logistics costs have started slowly reducing, and management expects some further reduction, though the magnitude is unknown.
• Insurance premiums rose sharply: This contributed to the increase in other expenses alongside logistics costs, and the current elevated level of other expenses is expected to largely continue.
• Market share prioritized over margin: The company is strongly focused on sustaining and possibly improving market share during difficult times, which may have pressured margins.
• Quarterly evaluation discouraged: Management stressed that product mix changes, volume differences, and dynamic raw material cost pass-through make annual evaluation more meaningful than quarterly.

Bimal Mehta: "For example sales of Rs.100 having various cost of Rs.80 would mean EBITDA of 20%. When the increase in cost of Rs.20 is added to the sales, the sales become 120 and cost would be 100, the EBITDA would be 16.67%. So this factor plays."

Capacity Expansion & Capex

• Primary approval granted after 6-7 year freeze: Until last year, no expansion permission had been given for six or seven years. A recent regulatory notification allowed Transpek to obtain primary approval for up to 450 metric tons per month of additional alkyl and acid chloride capacity, though the permission comes with many conditions and restrictions.
• Pollution constraints cap the real gain: The pollution control board does not permit any addition to current effluent or emission levels, so actual capacity increase may be limited to 200-250 MT despite the 450 MT primary approval, relying on technological innovations to stay within limits.
• Final approval timeline: At least three more months expected for final clearance.
• Plant replacement capex of ~₹35 Crores underway: An old plant for one existing product is being replaced with expanded capacity. The old plant will continue running while the new structure is built, with equipment moved later. Some inventory will be built up to fulfill orders during the transition, so no major revenue impact is expected.
• Volume realization from new plant: Higher volumes from the additional ~70% capacity expected to materialize over 18-24 months after the plant becomes operational.
• Additional revenue potential: Assuming 250 MT/month addition, another ₹50-60 Crores turnover can be added to the current ₹750-800 Crores level, depending on product mix. One product line expansion alone could add another ~₹20 Crores.
• No immediate major capex beyond this: Management is not aggressive on investments currently, preferring to deploy cashflow where it gives quick and good returns. Future capacity additions will depend on how new products perform in the market and customer response.
• Greenfield project on hold: A Greenfield site announced two-and-a-half years back was put on hold because the customer also paused expansion plans due to COVID. Engagement with those and other customers continues.
• Replacement capex is structural: Significant replacement capex is required every year due to the extremely corrosive nature of products, even without any expansion capex. If capex stays low, debt reduction will be substantial.

Bimal Mehta: "The pollution control board does not allow us to add a single kg or cubic meter to the current effluent or emission level. So it would be more of technological innovations and technological changes that would come into play..."

Demand & Volume Outlook

• Volumes restored to pre-COVID normalcy: Capacity utilization reached 90-92% in Q1, comparable to the consistent pre-COVID year FY2018-2019. FY21 was a COVID year with subdued volumes, and Q1 FY22 also had some COVID impact; stabilizing COVID conditions and improving shipping have helped restore volumes.
• Demand fundamentals remain strong: Acid and alkyl chloride demand is growing due to the increasing importance of chloride as a crucial component in pharmaceuticals, polymers, and other industries. The company's product outlook remains quite positive.
• Growth pace expected to moderate: Management cautioned against expecting exorbitant quarter-on-quarter numbers like 40-50% turnover changes. Moderate growth at a slow and steady pace is the expectation, given current complexities.
• New products seeded but early-stage: Four or five products have been added to the portfolio, with one slowly catching some volume. Each product has potential of around ₹10-20 Crores, with total potential reaching maybe ₹50-100 Crores once commercialized, but no specific timeline was given for when significant volumes will materialize.
• Non-chlorination products identified: Some products in the non-chlorination category have been identified and are in early stages, with more clarity expected in the coming period. Before committing major investments, the company is looking for strong and sustainable demand.
• Dispatch timing effect: Some dispatches from Q4 spilled over into Q1 FY2023 due to accounting policies around bill of lading and documentation timing, which is normal for export business.

Bimal Mehta: "Moving forward we should not see any such exorbitant numbers which are very high numbers in terms of quarter-on-quarter one but are moderate and we are working towards moderate growth at slow and steady pace considering current complexities whatever we can capture."

Europe Energy Crisis Risk

• Dual-channel threat: The expected energy crisis in Europe due to war and gas unavailability could impact Transpek in two ways: reduction in raw material supply if European companies cut production due to energy rationing, and reduction in demand from European customers if they cut production of products using Transpek's products.
• No impact yet, but vigilance high: As of the call date, no impact had been seen either way. Management is keeping continuous engagement with customers and will keep a very close watch on the situation.
• Raw material sourcing diversified: Imports come largely from three areas: China (not very significant), Europe, and Korea. No major issues seen so far from Korea or China despite COVID restrictions, though some minor delays and price increases have occurred. From Europe, no issues seen until now.

Bimal Mehta: "So far as I speak today we have not seen any impact both ways but we are keeping our fingers crossed, we are keeping engagement with our customers on a continuous basis and we would of course keep a very close watch on this but this is what the scenario is."

Product Mix & Revenue Complexity

• Sales value resists simple extrapolation: Product mix, regional pricing, logistics costs, and agent commissions vary significantly across products, countries, and customers, making arithmetic run-rate projections from capacity utilization unreliable. A product sold at \$3.5/kg in one quarter may see reduced volume next quarter, replaced by products at \$2.5/kg.
• Full-year sales estimate of ₹750-800 Crores: If current capacity utilization is sustained, management expects sales in this range, with some contribution from volume increase and some from cost pass-through into price.
• Long-term agreement disclosure declined: Management declined to disclose what percentage of sales comes from long-term agreements, citing competitive issues and confidentiality, but noted exports are significant and entire contract volumes go to exports only.
• Sellable capacity detail withheld: When asked for effective sellable capacity excluding captive consumption to understand realization, management declined to provide quantities, noting it varies by product (2 tonnes/day for one, 3 tonnes/day for another, 1.5 tonnes/day for another) and redirected to the absolute sales estimate.

Bimal Mehta: "it is a very complex kind of a mix of products, pricing, countries, customer so it is not something that is arithmetically easy to calculate and therefore based on what we understand in terms of our product mix we believe that we should be able to do anywhere between 750 to 800 Crores if we do more we all will be happy but at least at this point in time we are not seeing that."

Guidance & Commitments

Key Metrics